In State of the Heart, Dr. Haider Warraich takes readers inside the ER, inside patients' rooms, and inside the history and science of cardiac disease. State of the Heart traces the entire arc of the heart, from the very first time it was depicted on stone tablets, to a future in which it may very well become redundant. While heart disease has been around for a while, the type of heart disease people have, why they have it, and how it’s treated is changing. Yet, the golden age of heart science is only just beginning. And with treatments of heart disease altering the very definitions of human life and death, there is no better time to look at the present and future of heart disease, the doctors and nurses who treat it, the patients and caregivers who live with it, and the stories they hold close to their chests. More people die of heart disease than any other disease in the world and when any form of heart disease progresses, it can result in the development of heart failure. Heart failure affects millions and can affect anyone at anytime, a child recovering from a viral infection, a woman who has just given birth or a cancer patient receiving chemotherapy. Yet new technology to treat heart failure is fundamentally changing just what it means to be human. Mechanical pumps can be surgically sown into patients’ hearts and when patients with these pumps get really sick, sometimes they don’t need a doctor or a surgeon—they need a mechanic. In State of the Heart, the journey to rid the world of heart disease is shown to be reflective of the journey of medical science at large. We are learning not only that women have as much heart disease as men, but that the type of heart disease women experience is diametrically different from that in men. We are learning that heart disease and cancer may have more in common than we could have imagined. And we are learning how human evolution itself may have led to the epidemic of heart disease. In understanding how our knowledge of the heart evolved, State of the Heart traces the twisting and turning road that science has taken—filled with potholes and blind turns—all the way back to its very origin.

This book provides an exploration of the ethics of cardiology practice. It provides a variety of frameworks for analyzing ethical issues that arise in cardiovascular medicine. Cardiovascular medicine—the diagnosis and treatment of congenital and acquired diseases of the heart, major arteries, and veins—has seen rapid change in diagnosis, treatment, and the organization of practice in the last half of the twentieth and the beginning of the twenty first century. The complexity of these developments has resulted in increasing subspecialization, and many practitioners are challenged to stay abreast with the latest developments in cardiology. These changes also bring with them various ethical challenges. The chapters in this volume are divided by five broad areas of practice: beginning-of-life, end-of-life, transplantation and allocation of expensive or scarce resources, professionalism, and research. The case-based approach presented across the volume provides a perspective that will allow readers to reason through current and future ethical issues as they arise in this rapidly changing field. Ethical Issues in Cardiovascular Medicine will be of interest to researchers working in bioethics, clinical ethics, and the philosophy of medicine, as well as practicing physicians, nurses, and students who work in cardiovascular medicine.

This Annals volume stems from the two-day conference "Evolving Challenges in Promoting Cardiovascular Health" sponsored by The New York Academy of Sciences, "la Caixa" Foundation, and the International Center for Scientific Debate (ICSD), which took place November 4-5, 2011 in Barcelona, Spain. Leading and emerging investigators working on the fields of cardiology, vascular disease, inflammation, metabolic disorders, hematology, imaging, regenerative medicine, stem cell research, epidemiology, and nutrition, among others, address novel issues, current challenges, and future directions in the prevention, treatment, and management of the evolving global epidemic of cardiovascular disease. The papers in this volume explore the promotion of cardiovascular health through molecular biology, clinical pathophysiology, and population research. NOTE: Annals volumes are available for sale as individual books or as a journal. For information on institutional journal subscriptions, please visit http://ordering.onlinelibrary.wiley.com/subs.asp?ref=1749-6632&doi=10.1111/(ISSN)1749-6632. ACADEMY MEMBERS: Please contact the New York Academy of Sciences directly to place your order (www.nyas.org). Members of the New York Academy of Science receive full-text access to Annals online and discounts on print volumes. Please visit http://www.nyas.org/MemberCenter/Join.aspx for more information about becoming a member.

A significant medical event is expected in 1992: the first human use of a fully implantable, long-term cardiac assist device. This timely volume reviews the artificial heart program-and in particular, the National Institutes of Health's major investment-raising important questions. The volume includes: Consideration of the artificial heart versus heart transplantation and other approaches to treating end-stage heart disease, keeping in mind the different outcomes and costs of these treatments. A look at human issues, including the number of people who may require the artificial heart, patient quality of life, and other ethical and societal questions. Examination of how this technology's use can be targeted most appropriately. Attention to achieving access to this technology for all those who can benefit from it. The committee also offers three mechanisms to aid in allocating research and development funds.